913091-87-9

Upstream product

• 372-39-4 3,5-difluoroaniline 
• 140-89-6 potassium ethyl xanthogenate 

Downstream Products

• 1454250-96-4 (R)-N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454250-97-5 (S)-N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454250-93-1 N-([5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methyl)furo[2,3-c]pyridin-2-carboxamide 
• 1454252-75-5 [5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-yl]methanamine 
• 1454252-74-4 5-[(3,5-difluorobenzene)sulfinyl]pyridin-2-carbonitrile 
• 1454252-73-3 5-[(3,5-difluorophenyl)sulfanyl]pyridin-2-carbonitrile 
• 99389-26-1 3,5-difluorobenzenethiol 

Relevant academic research and scientific papers

Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase

A series of 17 novel 2-amino-4-oxo-5-[(substituted phenyl)thio]pyrrolo[2,3- d]pyrimidines were synthesized as potential inhibitors of thymidylate synthase (TS) and as antitumor agents. The analogues contain a variety of electron withdrawing substituents on the phenyl ring of the side chain and were evaluated as inhibitors of human TS (hTS) and Escherichia coli TS and of human and E. coli dihydrofolate reductase (DHFR). The analogues 14, 17, and 18 were potent inhibitors of hTS with IC50 values of 0.28, 0.21, and 0.22 μM, respectively, and were more potent than the clinically used ZD1694, 2 and LY231514, 3 against human TS.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

PYRIDYLMETHYLSULFONE DERIVATIVE

Disclosed is a novel compound having an effect of inhibiting the production/secretion of β-amyloid protein. A compound represented by the general formula (1) or a salt or a solvate of the compound or the salt; and a pharmaceutical agent comprising the compound, salt or solvate.

Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6- (arylthio)uracils

A series of 1-alkoxy-5-alkyl-6-(arylthio)uracils was synthesized and tested for their ability to inhibit HIV-1 replication. Treatment of 2-alkyl- 3,3-bis(methylthio)acryloyl chlorides (5a-e) with AgOCN in benzene followed by reaction of the resulting isocyanates 6a-e with an appropriate alkoxyamine gave N-alkoxy-N'-((2-alkyl-3,3-bis(methylthio)acryloyl)ureas (10a-z) in good to excellent yields. Cyclization of 10a-z in AcOH containing a catalytic amount of p-TsOH produced 1-alkoxy-5-alkyl-6-(methylthio)uracils (11a-z). Oxidation of 11a-z with 3-chloroperoxybenzoic acid in CH2Cl2 resulted in high yields of 1-alkoxy-5-alkyl-6-(methylsulfonyl)uracils (12a-x and 12z) and 1-(benzyloxy)-6-(methylsulfinyl)thymine (12y), which were subsequently reacted with an appropriate arenethiol in ethanolic NaOH solution to afford 1-alkoxy-5-alkyl-6-(arylthio)uracils (14-49). Substitution at the 3- and 5- positions of the C-6-(phenylthio) ring by two methyl groups significantly increased its original anti-HIV-1 activity (EC50: 6-((3,5- dimethylphenyl)thio)-5-isopropyl-1-propoxyuracil (18), 0.064 μM; 6-((3,5- dimethylphenyl)thio)-1-(3-hydroxypropoxy)-5-isopropyluracil (23), 0.19 μM). Among the various alkoxy substituents at the N-1, the propoxy group was the most beneficial for improving the anti-HIV-1 activity. The 1-propoxy derivative 18 proved to be the most potent inhibitor of HIV-1 replication, followed by the 1-(3-hydroxypropoxy) derivative 23. Introduction of an isopropyl group at C-5 of the uracil base also remarkably enhanced the activity. When compound 18 was incubated with a rat liver homogenate preparation, no metabolite was observed, thus confirming the metabolic stability of the N-O bond in these 1-alkoxyuracils.